

VivaZome executives to present at Annual Exosome Scientific Conference

3rd November; Melbourne, Australia: VivaZome Therapeutics Pty Ltd (VivaZome) is pleased to announce that its Head of Regulatory and Clinical, Ms Xenia Sango, is an invited speaker at the 5th Conference of the Australia and New Zealand Society for Extracellular Vesicles (ANZSEV) to be held in Gold Coast, Queensland on 9-11 November 2022. Ms Sango's presentation "Regulatory Affairs Relating to EV-based Therapeutics" will draw on her experience of over 30 years in the biotechnology and pharmaceutical sectors, including the registration of novel recombinant, plasma and vaccine products globally. She is a member of the International Society for Extracellular Vesicles (ISEV)'s Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics.

In addition, VivaZome's CEO, Dr David Haylock, and Ms Sango will be part of an Expert Panel Discussion on "How to go Commercial" at the ANZSEV Conference and are also invited participants in a conference-associated Cytiva workshop on 10 November.

Further, Dr Haylock and VivaZome Senior Scientist, Dr Smriti Krishna, are co-authors of the poster "Bioengineering exosomes to enhance brain targeting in a mouse traumatic brain injury model" by Dr Min Chen and colleagues from the University of Queensland.

ANZSEV is a membership organization that aims to promote the understanding, research and translation of Extracellular Vesicles (EVs) through an active national and international network and to create a common platform for members interested in EVs and nanoparticles. The ANZSEV Conference provides a world-class scientific program that focuses on advances in EV biology and technology, with broad impact and specific interest to delegates and Industry partners.

Dr Haylock stated: "VivaZome is delighted to be presenting at the ANZSEV Conference. We look forward to sharing our insights into the regulation and commercialisation of EV therapeutics at this major meeting".

For further information, contact:

Dr David Haylock, CEO, VivaZome Therapeutics Pty Ltd

David.haylock@vivazome.com

Phone: +61 (0) 439 617 657

About VivaZome:

VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at the La Trobe University Technology Enterprise Centre in Melbourne, Australia. VivaZome aims to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies and generating intellectual property that are applicable generically to exosome therapies. These will underpin the Company's development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

For more information, please visit www.vivazome.com